Efficacy of Solifenacin on Overactive Bladder Symptoms, Symptom Bother, and Other Patient-Reported Outcomes in Subjects With or Without Incontinence: A Post Hoc Analysis of Data From VIBRANT.

@article{Vardy2011EfficacyOS,
  title={Efficacy of Solifenacin on Overactive Bladder Symptoms, Symptom Bother, and Other Patient-Reported Outcomes in Subjects With or Without Incontinence: A Post Hoc Analysis of Data From VIBRANT.},
  author={Michael D. Vardy and H David Mitcheson and Terri-Ann Samuels and Sergio Forero-Schwanhaeuser and Weizhong He},
  journal={Female pelvic medicine & reconstructive surgery},
  year={2011},
  volume={17 1},
  pages={24-9}
}
OBJECTIVE : To evaluate the efficacy of solifenacin versus placebo by baseline continence status using post hoc analysis. METHODS : Patients with overactive bladder (OAB) were randomized to solifenacin or placebo for 12 weeks; patient-reported outcome (PRO) measures and bladder diaries were completed at prespecified time points. VESIcare Investigation of Bother and Quality of Life in Subjects with OAB (VIBRANT) was not designed to show treatment differences within continence status subgroups… CONTINUE READING